Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

For Alice Shaw, Dana-Farber Cancer Institute’s Chief of Strategic Partnerships, the best is however yet to come. “There is so much excitement around these RAS therapies,” says Shaw ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

Considering that the incidence of specific RAS mutations varies from cancer type to cancer type, it is clear the need for developing effective treatments against other RAS-mutations different to ...

RICHMOND - A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib—an FDA ...

A second drug candidate, BBO-10203, blocks the interaction between RAS and PI3K alpha ... evaluating BBO-10203 in advanced cases of breast cancer, colorectal cancer, and non-small cell lung ...

This South San Francisco company would be the first Bay Area biotech company to go public this year, proving that the SPAC ...

GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.